Albuminar Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Albuminar market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of hypoalbuminemia, expanded use in therapeutic and surgical applications, rising awareness of albumin's role in critical care, and government support for blood and plasma products.

The projected growth during the forecast period can be attributed to increased R&D and innovative product development, growing awareness and initiatives, the rise in cancer cases, expanding non-therapeutic applications, and the rising production of immunoglobulin. Key trends expected during this period include the integration of albumin in personalized medicine, a surge in clinical trials exploring new uses, expansion in emerging markets, advancements in manufacturing, improved formulations for enhanced efficacy, the development of new albumin-based products, and strengthened safety measures.

The rising incidence of burn injuries is expected to drive the growth of the albuminar market moving forward. Burn injuries are increasingly common due to factors such as greater exposure to household hazards, workplace accidents, fire-related incidents, wildfires, industrial accidents, and urban population growth. Albuminar (human albumin) is commonly used in the treatment of burn injuries, particularly in the early stages, to restore plasma volume, maintain blood pressure, and prevent shock. For instance, the American Burn Association reported in August 2024 that there were 32,540 burn cases in 2023, an increase from 30,135 cases in 2022, contributing to a total of 156,073 cases over the last five years. This rising incidence of burn injuries is driving the demand for albuminar.

An increasing number of surgical procedures is expected to propel the growth of the albuminar market. The rise in chronic lifestyle diseases and advancements in medical technology have led to greater demand for surgical procedures. Innovations in medical technology have improved the effectiveness and accessibility of surgeries, meeting the growing healthcare needs. Albuminar is used during surgeries to restore blood volume, maintain circulatory stability, and address hypoalbuminemia, particularly in major trauma, cardiac, liver transplantation, and orthopedic procedures. For example, the UK Health Security Agency reported in December 2023 that the number of coronary artery bypass graft surgeries increased in 2023, with 27,524 surgeries performed compared to previous years. The increasing number of surgical procedures is thus driving the growth of the Albuminar market.

A key trend in the albuminar market is the adoption of strategic partnerships to enhance technology integration and expand market reach. Strategic partnerships allow organizations to combine resources and expertise to achieve common goals. For instance, in April 2023, Kedrion Biopharma Inc., a US-based pharmaceutical manufacturer, partnered with BPL, a UK-based company, to launch a human albumin product in the Chinese market following approval from China’s National Institutes for Food and Drug Control (NIFDC). This collaboration strengthens Kedrion’s position as a global leader in plasma products and expands its market reach, employing over 5,000 people worldwide and operating 73 plasma collection centers in the U.S. and five in the Czech Republic.

Key player operating in the albuminar market is CSL Behring LLC.

North America was the largest region in the Albuminar market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuminar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Albuminar is a human albumin solution derived from plasma, primarily used to restore blood volume and maintain oncotic pressure. It is commonly prescribed for conditions such as hypovolemia, hypoalbuminemia, and shock. Administered intravenously, it helps stabilize fluid balance in critically ill or injured patients.

The main formulations of albuminar include human serum albumin, bovine serum albumin, and recombinant albumin. Human serum albumin (HSA) is the most abundant protein in human blood plasma, produced by the liver. It plays a vital role in maintaining oncotic pressure, which helps keep fluid within the bloodstream and prevents it from leaking into tissues. Albuminar is indicated for shock treatment, burns, hypoalbuminemia, and other related conditions. Its end users include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.

The albuminar market research report is one of a series of new reports that provides albuminar market statistics, including albuminar industry global market size, regional shares, competitors with a albuminar market share, detailed albuminar market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar industry. This albuminar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albuminar market consists of sales of Albuminar 5% and Albuminar 20%. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.